Treatment with lipid nanoparticle (LNP)-formulated anti-HOXB-AS3 gapmers led to downregulation of HOXB-AS3 expression in human CD45-selected AML blasts isolated from the BM of the treated mice (P < 0.001; Fig. 3c). The gene discussed is PDS5B; the disease is acute myeloid leukemia.